HealthPartners Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bloomington MN United States (1957)

Organization Overview

First Clinical Trial
2003
NCT00202059
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Health Partners Institute | HealthPartners Institute | HealthPartners Institute dba International Diabetes Center | HealthPartners Institute Regions Cancer Care Center | HealthPartners Institute / Regions Hospital | HealthPartners Neurology | HealthPartners Neuroscience Research | HealthPartners Regions Cancer Care and Frauenshuh Cancer Care Centers | Medical Director, Regions Hospital/HealthPartners Sleep Center | Regions Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Anorexia (Phase 4)

Anorexia Nervosa (Phase 4)

Anxiety Disorders (Phase 4)

Aphasia, Primary Progressive (Phase 2)

Arthralgia (Phase 2)

Breast Neoplasms (Phase 3)

Burns (Phase 4)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Small Cell (Phase 1)

Cognitive Dysfunction (Phase 4)

Dementia (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Down Syndrome (Phase 1)

Feeding and Eating Disorders (Phase 4)

Frontotemporal Dementia (Phase 2)

Hemorrhage (Phase 4)

Hyperglycemia (Phase 4)

Hypoglycemia (Phase 2)

Lung Neoplasms (Phase 1)

Melanoma (Phase 2)

Mesothelioma (Phase 2)

Myalgia (Phase 2)

Parkinson Disease (Phase 4)

Pick Disease of the Brain (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Syndrome (Phase 1)

Thinness (Phase 4)

Urinary Bladder, Overactive (Phase 4)

Uveal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial APIs: 33